Anti-Aids drug Isentres is eligible for FDA priority review
-
Last Update: 2020-07-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Mercado Hass, inc., has announced that its anti-AIDS drug Isentres, which it is developing, has been granted fda-prioritized fda status by the U.SFDA, meaning the agency will make a decision on whether to approve the drug within six monthsMercayon expects the FDA to make a decision by mid-OctoberIf approved, it would be the first drug in a new generation to be approved for saleIt is reported that Mershadon is also seeking isentres and other antiviral drugs to use the treatment of AIDS approvalMercado said the company is submitting applications for the drug to other countries and is conducting clinical trials to treat AIDS patients who have never been treated
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
